Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Voting Common Shares, no par value
-
Shares outstanding
-
51.9M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
2.57M
-
Shares change
-
+41.2K
-
Total reported value, excl. options
-
$3.92M
-
Value change
-
+$61.6K
-
Put/Call ratio
-
0.09
-
Number of buys
-
8
-
Number of sells
-
-8
-
Price
-
$1.53
Significant Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q1 2023
28 filings reported holding DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value as of Q1 2023.
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.57M shares
of 51.9M outstanding shares and own 4.94% of the company stock.
Largest 10 shareholders include COOPERMAN LEON G (868K shares), VANGUARD GROUP INC (783K shares), JACOB ASSET MANAGEMENT OF NEW YORK LLC (234K shares), GEODE CAPITAL MANAGEMENT, LLC (185K shares), NORTHERN TRUST CORP (90.8K shares), BlackRock Inc. (71.7K shares), STATE STREET CORP (66.6K shares), RENAISSANCE TECHNOLOGIES LLC (64.5K shares), MORGAN STANLEY (57.2K shares), and CITADEL ADVISORS LLC (42.2K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.